局限期小细胞肺癌治疗现状和免疫治疗研究进展  

Current Status and Research Progress of Immunotheray for Limited Stage Small Cell Lung Cancer

作　　者：饶创宙[1] RAO Chuangzhou(Ningbo No.2 Hospital,Ningbo 315010,China)

机构地区：[1]宁波市第二医院,浙江宁波315010

出　　处：《肿瘤学杂志》2024年第12期982-990,共9页Journal of Chinese Oncology

基　　金：宁波市医学重点学科-肿瘤学(2022-B09)。

摘　　要：局限期小细胞肺癌生长迅速且转移率高,预后差,除了极少数早期患者存在手术机会外,化疗联合放疗的综合治疗仍然是不可手术的局限期小细胞肺癌的标准治疗方式。免疫治疗的出现,为小细胞肺癌带来新的曙光。目前,放化疗联合免疫治疗的探索有获益,也有不足,是当前小细胞肺癌领域的研究热点。全文总结了局限期小细胞肺癌放化疗联合免疫治疗策略的探索,包括免疫治疗介入的时机(放化疗后免疫巩固治疗、放化疗期间联合免疫治疗)、不同作用机制药物及组合(PD-L1/PD-1抑制剂、CTLA-4抑制剂、抗BTLA抗体、TIGIT抗体和DLL3抗体),以及在免疫治疗时代,放疗高低剂量及分割模式的探索。免疫治疗在常规标准放化疗疗程中如何更好增强抗肿瘤免疫效应是未来值得进一步探索的方向。Limited stage small cell lung cancer(SCLC)has strong invasiveness and poor prognosis.Except for a few patients in the very early stage who have the opportunity for surgery,concurrent chemoradiotherapy remains the standard treatment for non-surgical limited stage SCLC.The emerging immunotherapy has brought opportunities for SCLC,meanwhile,the combination of chemoradiotherapy with immunotherapy has both benefits and shortcomings,making it a research hotpot in SCLC treatment.This paper reviews the current status and research progress of immune checkpoint inhibitor(ICI)therapy,including the timing of immunotherapy intervention(immunotherapy following concurrent/sequential chemoradiotherapy,immunotherapy in combination with concurrent/sequential chemoradiotherapy),the combination of different ICIs(PD-L1/PD-1 inhibitors,CTLA-4 inhibitors,anti-BTLA,TIGIT antibodies,DLL3 antibodies),and the doses of radiotherapy and fractionation patterns with immunotherapy.The current progress in this field indicates that the potential of immunotherapy during standard radiotherapy and chemotherapy is worth further exploring.

关 键 词：小细胞肺癌 局限期 免疫疗法 放疗疗法 临床研究 

分 类 号：R734.2[医药卫生—肿瘤]